Antonia Gabriel

Antonia Fettelschoss-Gabriel, PhD
Tel +41 44 556 3265 

Fettelschoss-Antonia-Nov 2018.png

​​Main field of research
Our main research area is translating immunology of chronic diseases or hyperreactivities such as allergies into new cutting-edge therapeutic vaccines. Our virus-like particle (VLP)-based therapeutic vaccines target key molecules involved in disease pathology and, in contrast to other biologicals, are an inexpensive and effective way of treating chronic disorders. Thus, advanced technology can become available even to our companion animals. One of our main interests are skin-related problems in horses. The most common chronic allergic dermatitis in horses is caused by insect bites. Insect-bite hypersensitivity (IBH)-affected horses suffer from pruritic skin lesions, caused by type-I/type-IVb allergic reactions accompanied by prominent eosinophilic infiltration into the skin. We study the interplay of underlying allergic reactions in early and chronic stages of disease. IBH in horses shares common features with human asthma. Thus, we believe understanding the molecular mechanisms in such allergic reactions can be translated to other species including humans allowing to improving treatment modalities in the future.

Selected references

  • Active vaccination against Interleukin-5 as long-term treatment for insect bite hypersensitivity in horses. Allergy 2019, 74:572-582.
  • Treating insect-bite hypersensitivity in horses with active vaccination against IL-5. J Allergy Clin Immunol 2018, 142:1194-1205.
  • Inflammasome activation and IL-1b target IL-1a for secretion as opposed to surface expression. Proc Natl Acad Sci U S A, 2011,108:18055-60.

Publications (PubMed)

Group Members
Victoria Fettelschoss, MSc, Research associate
Florian Olomski, MSc, Research associate

Juwela Lam, Msc, Research Associate
Katharina Birkmann, DVM
Tanya Rhiner, DVM candidate

Thomas Kündig & Pål Johansen

Prof. Thomas Kündig, MD, Chair of Department of Dermatology
Tel +41 44 255 3471 (secr.)

Prof. Pål Johansen, PhD
Tel +41 44 255 8616


Main fields of research
Our research group is focused on immunotherapy of allergies, infections, and cancer. In allergy, we aim to improve efficacy and safety for immunotherapy by using novel methods or technologies. For instance, we found that administration of allergens into lymph nodes allowed shortening immunotherapy from three years of 50-60 injection to merely three injections during two months, and more recently, we are investigating the potential of allergen-specific monoclonal antibodies for use in allergen immunotherapy. We have also been strongly involved in the development of new adjuvants or particulate vaccines for immunotherapy. For instance, virus-like particles and liposomes are investigated for their potential in inducing immune responses in allergy and inflammatory skin disorders, as well as in conditions of immune suppression or deficiency, while liposomes rendered T-cell independent antibody production. Finally, we are developing a new method of cancer vaccination by combining vaccines and photodynamic therapy (PDT), a method that enables the induction of cytotoxic and tumour-specific T-cell responses. Many of our research projects are performed in collaboration with biotech companies and aim to facilitate the translation of new technologies and new treatment options into clinics and ultimately to make these available to patients.
Publications (PubMed)

Group Members
Team Gloriastrasse
Ying Men-Wäckerle, PhD
Fabio Hasler, PhD student
Marta Paolucci, PhD student
Zuzanna Kotkowska, PhD student
Deborah Leuthard, MD
Lara Sosic, MD student
Alina Müller, MD student
Lucy Hausammann, Master student
Agathe Duda, Research associate

Team Schlieren
Gery Jennings, PhD
Senta Walton, PhD
Grace Gordon, Research associate


Steve Pascolo

PD Steve Pascolo, PhD



Group Member
Natalia T. Jarzebska , PhD student

We use cookies to make our website user-friendly, to continuously improve it and to analyze the traffic of our website. By continuing to browse the site, you are agreeing to our use of cookies. Further information can be found in our privacy policy.